Esperion Therapeutics (ESPR) Cash from Financing Activities (2012 - 2026)

Esperion Therapeutics' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at $16.2 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 316.23% year-over-year to $16.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.9 million (up 615.41% YoY) and the FY2025 annual result came in at $36.2 million, down 58.16% from the prior year.
• Cash from Financing Activities was $16.2 million for Q1 2026 at Esperion Therapeutics, down from $30.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $90.6 million in Q1 2024 and bottomed at -$30.4 million in Q4 2022.
• A 5-year average of $13.1 million and a median of $4.5 million in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 3546.52% — and 2024, when it tumbled 3811.12%.
• Esperion Therapeutics' Cash from Financing Activities stood at -$30.4 million in 2022, then jumped by 114.73% to $4.5 million in 2023, then soared by 682.73% to $35.0 million in 2024, then retreated by 13.81% to $30.2 million in 2025, then tumbled by 46.23% to $16.2 million in 2026.
• Business Quant data shows ESPR's Cash from Financing Activities at $16.2 million in Q1 2026, $30.2 million in Q4 2025, and $10.7 million in Q3 2025.